Navigation Links
Preliminary Financial Results, Quarterly Reports and Upcoming Conference Schedules - Research Report on Avanir, BioScrip, Chemed, Foundation Medicine, and Antares
Date:11/11/2013

NEW YORK, November 11, 2013 /PRNewswire/ --

Editor Note: For more information about this release, please scroll to bottom.

Today, Analysts' Corner announced new research reports highlighting Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR), BioScrip, Inc. (NASDAQ: BIOS), Chemed Corporation (NYSE: CHE), Foundation Medicine, Inc. (NASDAQ: FMI), and Antares Pharma, Inc. (NASDAQ: ATRS). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.

Avanir Pharmaceuticals, Inc. Research Report

On October 29, 2013, Avanir Pharmaceuticals, Inc. (Avanir) reported preliminary financial information for full-year FY 2013 (period ended September 30, 2013). Based on the preliminary financial information reported by the Company, total gross revenues for full-year FY 2013 are estimated to be nearly $95.9 million, while net revenues are estimated to be between $75.3 million to $76.3 million. "We are delighted with the progress of our NUEDEXTA PBA commercial business this year," said Keith Katkin, President and CEO of Avanir. "In addition, the R&D team has made great progress with our pipeline. We now have three active phase II studies of AVP-923 including MS neuropathic pain, Alzheimer's agitation, and the recently announced levodopa-induced dyskinesias in Parkinson's disease. We continue to expect top-line data from our PRIME study in MS neuropathic pain later this calendar year." The Full Research Report on Avanir Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

[http://www.analystscorner.com/r/full_research_report/2ee8_AVNR]

--

BioScrip, Inc. Research Report

On November 6, 2013, BioScrip, Inc. (BioScrip) reported its Q3 2013 financial results. During the quarter, the Company's revenue increased 22.6% YoY to $208.9 million. Q3 2013 net loss from continuing operations was $22.4 million, or $0.35 per diluted share, compared with a net loss of $0.6 million or $0.01 per diluted share, in Q3 2012. "Our core infusion business continued to deliver strong margins and double-digit organic revenue growth in the third quarter," said Rick Smith, President and CEO of BioScrip. "We closed the CarePoint acquisition during the quarter and our acquisitions are on track to achieve their targeted range of 12 to 14 percent long-term EBITDA margins, once fully integrated. These underlying results demonstrate our success in implementing our plan to deliver growth across a national infusion footprint." The Full Research Report on BioScrip, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

[http://www.analystscorner.com/r/full_research_report/4879_BIOS]

--

Chemed Corporation Research Report

On November 6, 2013, Chemed Corporation (Chemed) announced that it will make a presentation at the 2013 Credit Suisse Healthcare Conference. The Company informed that the presentation will take place on November 12, 2013 at approximately 8:00 a.m. MT at the Phoenician Hotel in Scottsdale, AZ. The presentation will be webcast live and can be accessed through the Chemed website. The Full Research Report on Chemed Corporation - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

[http://www.analystscorner.com/r/full_research_report/4c0d_CHE]

--

Foundation Medicine, Inc. Research Report

On November 6, 2013, Foundation Medicine, Inc. (Foundation Medicine) reported its Q3 2013 financial results. During the quarter, the Company's revenues totaled $8.2 million, up 170.3% YoY. The Company informed that more than half of its quarterly revenues came from clinical testing. Q3 2013 net loss was $12.5 million, or $3.51 loss per basic and diluted share, compared with a net loss of $5.6 million, or $2.39 per basic and diluted share, in Q3 2012. "Results in the third quarter demonstrate the growing enthusiasm in the marketplace for our fully informative genomic profile for use across all solid tumors," said Michael Pellini, M.D., President and CEO of Foundation Medicine. "We are very encouraged by the commercial traction as the utility of FoundationOne and the information it delivers garners growing recognition among oncologists, pathologists and pharmaceutical companies. In addition, the number of scientific publications generated using our molecular information platform during the quarter continues to underscore its clinical utility and value in the care of patients with cancer." The Full Research Report on Foundation Medicine, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

[http://www.analystscorner.com/r/full_research_report/d9a0_FMI]

--

Antares Pharma, Inc. Research Report

On November 6, 2013, Antares Pharma, Inc. (Antares) reported its Q3 2013 financial results. The Company's revenues totaled $5.5 million, down 3.1% YoY during the quarter. Q3 2013 net loss was $0.05 per basic and diluted share, compared with a net loss of $0.03 per basic and diluted share, in Q3 2012. "Last month's approval of OTREXUP represented a strategic milestone in the transformation of Antares from a royalty based business to a specialty pharmaceutical company generating potential product revenue from proprietary in-house development programs," said Paul K. Wotton, Ph.D., President and CEO of Antares. "We believe that OTREXUP could become an important part of the treatment continuum for RA patients and look forward to launching the product early in 2014." The Full Research Report on Antares Pharma, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

[http://www.analystscorner.com/r/full_research_report/2353_ATRS]

----

EDITOR NOTES:

  1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
  2. Information in this release is fact checked and produced on a best efforts basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
  3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
  4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com.
  5. For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com.
  6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Ananya Ghosh, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

http://AnalystsCorner.com

 


'/>"/>
SOURCE Analysts' Corner
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Preliminary Phase 2 Data of Ocera Therapeutics OCR-002 for the Treatment of Liver Cirrhosis and Upper GI Bleeding Show Potent Ammonia Reduction
2. OncoSec Presents Preliminary Safety Data for Phase II Melanoma Study at Second European Post-Chicago Melanoma Meeting 2012
3. Pro-Dex Provides Insight Into Fiscal 2013 Operating Plan And Preliminary Results For Fiscal 2012
4. Simcere Pharmaceutical Group Reports Preliminary Unaudited Second Quarter 2012 Results
5. Lexicon Pharmaceuticals Reports Preliminary Results From Two Phase 1 Studies
6. CareFusion To Report Preliminary Fiscal 2013 First Quarter Results On Nov. 8
7. Cardinal Health Announces Preliminary Shareholder Voting Results at 2012 Annual Meeting
8. CareFusion Reports Preliminary First Quarter Fiscal 2013 Results
9. OncoSec Medical Reports Positive Preliminary Efficacy Results from Phase II Study of ImmunoPulse in Metastatic Melanoma Patients
10. Simcere Pharmaceutical Group Reports Preliminary Unaudited Third Quarter 2012 Results
11. Avanir Pharmaceuticals Pre-Announces Preliminary Fiscal 2012 Fourth Quarter Results And Provides Clinical Study Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... LEXINGTON, Mass. , June 24, 2016   ... specialty pharmaceutical company developing innovative inhaled drugs, announced today ... when Russell Investments reconstituted its comprehensive set ... 2016. "This is an important milestone for ... "It will increase shareholder awareness of our progress in ...
(Date:6/23/2016)... 23, 2016 Research and Markets has ... - Forecast to 2022" report to their offering. ... for the patients with kidney failure, it replaces the function ... the patient,s blood and thus the treatment helps to keep ... in balance. Increasing number of ESRD patients ...
(Date:6/23/2016)... June 23, 2016 Roche (SIX: RO, ROG; ... for its Elecsys BRAHMS PCT (procalcitonin) assay as a ... septic shock. With this clearance, Roche is the first ... integrated solution for sepsis risk assessment and management. ... infection and PCT levels in blood can aid clinicians ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... June 27, 2016 , ... "FCPX editors can now reveal their media ... Pro X," said Christina Austin - CEO of Pixel Film Studios. , ProSlice ... X users can now reveal the media of their split screens with growing ...
(Date:6/27/2016)... ... June 27, 2016 , ... ... strategic partnership with Connance, a healthcare industry leader providing predictive analytics to ... technology combine to provide health systems, hospitals and ambulatory surgical centers with ...
(Date:6/27/2016)... ... 2016 , ... TopConsumerReviews.com recently awarded their highest five-star rating to Best Buy ... in the United States and Canada wear eyeglasses. Once considered to be a purely ... make a fashion statement. Even celebrities use glasses as a way of creating an ...
(Date:6/26/2016)... ... June 26, 2016 , ... On June 10-11, 2016, A ... 2016 Cereal Festival and World’s Longest Breakfast Table in Battle Creek, MI, where the ... history as home to some of the world’s leading providers of cereal and other ...
(Date:6/26/2016)... Cary, North Carolina (PRWEB) , ... June 26, 2016 , ... ... the release of a new product that was developed to enhance the health of ... harvested for centuries. , The two main herbs in the PawPaws Cat Kidney ...
Breaking Medicine News(10 mins):